Abstract

Haemonetics will report fiscal Q1 2027 results on August 06, 2025 Pre-Market; this preview summarizes the prior quarter’s trends, current-quarter revenue and profit forecasts, and how segment dynamics may shape investor expectations.

Market Forecast

Based on the company’s guidance framework and market modeling, Haemonetics’ current quarter is forecast at total revenue of 327.89 million US dollars, up 7.73% year over year, with EBIT estimated at 77.71 million US dollars and adjusted EPS at 1.08; the year-over-year growth assumptions are 6.45% for EBIT and 5.99% for EPS. Margin commentary is cautious-to-stable: gross margin is expected to remain near upper-50s on product mix and manufacturing efficiencies, while net margin should improve alongside operating leverage; the year-over-year comps imply modest expansion if execution holds. Main businesses are expected to show mixed but constructive demand signals: Hospital products and services, Plasma products and services, and Blood Center are set to contribute the bulk of revenue with resilience in capital and disposables supporting throughput across the installed base and continued software and service uptake. The segment with the largest growth potential remains Plasma products and services, supported by continued donor-center investment and utilization; this business was 130.29 million US dollars last quarter and is set up for mid-to-high single-digit year-over-year growth on stable procedure volumes and mix.

Last Quarter Review

Haemonetics’ previous quarter posted revenue of 346.35 million US dollars, a gross profit margin of 57.24%, GAAP net profit attributable to the parent company of -20.15 million US dollars, a net profit margin of -5.82%, and adjusted EPS of 1.29, reflecting a 4.77% year-over-year revenue increase and a 4.03% year-over-year rise in adjusted EPS. A key financial highlight was better-than-expected revenue delivery versus internal and external estimates, with EBIT of 84.50 million US dollars and positive year-over-year growth; however, GAAP profitability reflected non-operating or non-recurring items that weighed on the bottom line. By business, Hospital products and services generated 159.65 million US dollars, Plasma products and services delivered 130.29 million US dollars, and Blood Center contributed 56.41 million US dollars; management emphasized steady demand across disposables and procedure kits, with stable utilization across accounts.

Current Quarter Outlook (with major analytical insights)

Hospital products and services: steady disposables and procedural throughput underpin revenue stability

Hospital products and services is the largest revenue contributor and a stabilizing force in Haemonetics’ portfolio. The combination of an installed base of devices and recurring disposables tends to produce predictable volumes through normal seasonality. For the current quarter, the model-implied outlook points to balanced demand, with price and mix tailwinds expected to offset input-cost variability. Procurement cycles in hospital systems have normalized compared with pandemic-era patterns, and procedure volumes are holding, helping sustain high-50s gross margin for the consolidated business. From an operating standpoint, supply chain continuity and manufacturing productivity remain crucial to protecting contribution margin; any incremental logistics or component inflation is likely to be managed through efficiencies and selective pricing. Taken together, this segment should provide a solid base for revenue and cash generation this quarter, anchoring overall profitability even if other segments exhibit variability.

Plasma products and services: the key growth engine with favorable utilization and network expansion

Plasma remains the clearest growth driver in the model, supported by sustained donor-center activity and network optimization. The prior quarter’s 130.29 million US dollars in revenue sets a solid run-rate, and current-quarter assumptions imply mid-to-high single-digit year-over-year growth as procedure volumes and kit pull-through stay firm. Growth is underpinned by steady investment in plasma collection footprint and ongoing productivity initiatives at centers, which support throughput and consumable demand. On margins, scale benefits and manufacturing efficiency should help maintain gross margin resilience, while product mix improvements can provide an additional lift. Key watch items include any regional fluctuations in donor availability and cadence of center openings or refurbishments, which could influence near-term volumes. Even with these variables, the demand environment suggests Plasma should again outpace corporate-average growth and serve as the primary lever for revenue upside versus the forecast.

Blood Center: normalization continues, with disciplined portfolio management

Blood Center’s contribution of 56.41 million US dollars last quarter reflects a smaller, more mature revenue stream that benefits from disciplined commercial execution. The outlook for this quarter indicates stable-to-modest growth as customer activity maintains a steady cadence and modernization initiatives support operational efficiencies. Management attention to portfolio productivity and selective pricing is important to defend profitability, especially where scale is lower and competitive dynamics can tighten. From a stock perspective, this segment is less likely to drive estimate revisions but can support total margin stability if operating discipline persists. Investors should monitor contract timing and standardized product transitions, which can cause intra-quarter lumpiness but usually normalize over the fiscal year.

Stock-price drivers this quarter: gross margin trajectory, GAAP-to-adjusted EPS gap, and top-line versus forecast

The first determinant for share reaction is gross margin trajectory relative to the prior quarter’s 57.24%. With EBIT modeled to grow 6.45% year over year and revenue up 7.73%, margin stability or improvement would confirm operating leverage and help narrow the GAAP-to-adjusted gap. Conversely, any adverse mix or transitory cost pressures could compress gross margin and weigh on sentiment. The second driver is the reconciliation between GAAP net income and adjusted metrics. The prior quarter’s GAAP net loss alongside positive adjusted EPS highlights the importance of understanding one-time items. If the company demonstrates fewer non-recurring charges and cleaner GAAP earnings in the current quarter, the credibility of the earnings quality improves, supporting valuation. The third driver is top-line performance versus the 327.89 million US dollars forecast. Upside to revenue typically reflects stronger disposables utilization in Hospital and Plasma and can translate into EBIT and EPS beats; downside would most likely stem from timing of orders, donor center cadence, or supply chain noise. Guidance tone for the rest of the fiscal year will also anchor post-print expectations and could be as influential as the headline numbers.

Analyst Opinions

Across recent institutional commentary, the majority view is constructive: favorable into-print expectations center on resilient Plasma demand, stable Hospital utilization, and disciplined cost execution, which together support mid-single to high-single-digit growth in revenue and earnings. Bullish voices argue that the current-quarter revenue forecast of 327.89 million US dollars and adjusted EPS of roughly 1.08 are well calibrated, with upside risk if plasma utilization trends outperform and mix remains favorable. On the other hand, the smaller camp with a cautious stance points to the prior quarter’s GAAP loss and the potential for transitory cost or mix headwinds that could mute margin expansion; yet even these perspectives acknowledge ongoing structural demand in core franchises. The dominant bullish view emphasizes three points. First, execution in Plasma is viewed as durable, given sustained donor-center activities and procedural throughput, positioning this franchise to outgrow the corporate average and support consolidated margin defense. Second, Hospital’s recurring disposables base provides visibility into near-term revenue, helping smooth volatility and offer a dependable cash-flow stream. Third, with EBIT forecast to grow 6.45% year over year and EPS up 5.99%, the operating framework suggests manageable inflation and solid productivity, which increases the probability of meeting or exceeding the consensus-like model. Institutions also highlight that if GAAP and adjusted results converge as non-recurring items fade, valuation support improves and could attract broader participation. Overall, the balance of commentary indicates cautious optimism heading into the print, with revenue, gross margin steadiness, and the pace of Plasma growth as the key validation points investors will scrutinize.